Yesterday, FDA's Digital Health Center of Excellence published something it was careful to call a discussion paper rather than guidance: a 30-page document laying out considerations for regulating generative AI-enabled medical devices, opening a public comment docket that runs until October 19. The agency has been explicit that this isn't draft policy — it doesn't propose regulatory expectations, doesn't address whether new legal authority would be needed, and doesn't commit